GlaxoSmithKline begins new trial of triple combination therapy for COPD

GlaxoSmithKline and Theravance have commenced a second global phase III study of a new once-daily closed triple combination therapy for chronic obstructive pulmonary disease (COPD).

The Fulfil study will enrol approximately 1,800 patients and will assess the safety and efficacy of a combination of fluticasone furoate, umeclidinium and vilanterol, all delivered via GlaxoSmithKline's Ellipta inhaler.

Specifically, it will look at whether the new combination can improve lung function and health-related quality of life compared with budesonide/formoterol, a twice-daily combination delivered via the Turbohaler dry powder inhaler.

The first, larger study in the phase III programme, known as IMPACT, started in July 2014 to assess whether the new treatment option can reduce the rate of moderate and severe exacerbations compared with two approved once-daily COPD treatments.

Dave Allen, head of research and development at GlaxoSmithKline's respiratory therapy area unit, said: "We hope to offer more convenient dosing to patients, reduce the risk of exacerbation compared to dual therapy and, as a result, contribute to the improved management of their disease."

COPD is an important area of focus for GlaxoSmithKline and Theravance. The partners received European approval for another COPD therapy, Anoro, last year.